May 5, 2026 01:05PM Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

Apr 30, 2026 09:15AM OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

Apr 29, 2026 09:50AM OSR Holdings signs $815 million license deal for VXM01 drug candidate

Apr 29, 2026 09:50AM OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

Apr 9, 2026 09:16AM OSR Holdings retires $2.02 million in warrants through convertible note

Apr 9, 2026 09:15AM OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

Mar 30, 2026 09:00AM OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

Mar 27, 2026 09:00AM Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

Mar 23, 2026 08:40AM OSR Holdings restructures $815 million VXM01 licensing deal

Mar 23, 2026 08:30AM OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

Mar 19, 2026 09:45AM OSR Holdings unit signs NDA with China's Sinopharm for glucose tech

Mar 19, 2026 08:55AM Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities

Mar 5, 2026 09:31AM OSR Holdings receives 180-day NASDAQ extension until August 31

Mar 5, 2026 09:30AM OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum

Feb 2, 2026 09:57AM OSR Holdings advances biotech licensing deal worth up to $815 million

Feb 2, 2026 09:50AM CEO Statement to Shareholders

Jan 27, 2026 08:32AM OSR Holdings completes Woori IO acquisition, reviews device unit merger

Jan 27, 2026 08:30AM OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

Jan 16, 2026 09:24AM Vaximm names Sébastien Wieckowski as chief scientific officer

Jan 14, 2026 09:29AM Vaximm enters $845 million licensing deal for oral cancer therapy

Dec 19, 2025 11:51AM OSR Holdings completes acquisition of Korean glucose monitor firm

Dec 4, 2025 03:19PM Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement

Nov 21, 2025 09:20AM Vaximm enters licensing term sheet with BCM Europe for cancer therapy

Oct 20, 2025 11:40AM Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target

Jul 31, 2025 12:46PM OSR Holdings issues 2.3 million shares under structured financing

Jul 30, 2025 04:11PM OSR Holdings updates Woori IO acquisition structure

Jul 15, 2025 07:30AM OSR Holdings names Dr. Andreas Niethammer CMO of Vaximm AG subsidiary

Jul 9, 2025 07:59AM OSR Holdings plans $50 million security token offering for late 2025

Jul 8, 2025 10:04AM OSR Holdings plans $50 million security token offering for second half 2025

Apr 3, 2025 07:31AM OSR Holdings (OSRH) Enters Into $80M Common Stock Purchase Agreement With White Lion GBM Innovation Fund

Mar 26, 2025 07:19AM OSR Holdings' (OSRH) Vaximm AG Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

Mar 25, 2025 07:02AM OSR Holdings (OSRH) Appoints Constance Höfer as Chief Scientific Officer